Beam Therapeutics Inc. Financials
This page shows Beam Therapeutics Inc. (BEAM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Beam’s smaller reported loss hides a cash-hungry, research-led model that still depends on equity financing to operate.
FY2025 net loss narrowed to-$80.0M from-$376.7M , but that improvement did not show up in cash generation. Operating cash flow remained deeply negative at-$345.1M and free cash flow at-$360.0M , implying the better earnings figure came more from accounting items than from a cheaper operating engine, and the underlying cash cost of running the platform barely changed.
R&D spending reached
Shares outstanding rose to 101.7M from 83.6M in FY2025. Combined with
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Beam Therapeutics Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Beam Therapeutics Inc. scores 6.52, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.2B) relative to total liabilities ($242.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Beam Therapeutics Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Beam Therapeutics Inc. generates $4.31 in operating cash flow (-$345.1M OCF vs -$80.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Beam Therapeutics Inc. generated $139.7M in revenue in fiscal year 2025. This represents an increase of 120.0% from the prior year.
Beam Therapeutics Inc.'s EBITDA was -$361.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 8.2% from the prior year.
Beam Therapeutics Inc. reported -$80.0M in net income in fiscal year 2025. This represents an increase of 78.8% from the prior year.
Beam Therapeutics Inc. earned $-0.81 per diluted share (EPS) in fiscal year 2025. This represents an increase of 82.3% from the prior year.
Cash & Balance Sheet
Beam Therapeutics Inc. generated -$360.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 1.1% from the prior year.
Beam Therapeutics Inc. held $294.9M in cash against $0 in long-term debt as of fiscal year 2025.
Beam Therapeutics Inc. had 102M shares outstanding in fiscal year 2025. This represents an increase of 21.7% from the prior year.
Margins & Returns
Beam Therapeutics Inc.'s operating margin was -274.6% in fiscal year 2025, reflecting core business profitability. This is up 379.7 percentage points from the prior year.
Beam Therapeutics Inc.'s net profit margin was -57.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 535.9 percentage points from the prior year.
Beam Therapeutics Inc.'s ROE was -6.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 44.9 percentage points from the prior year.
Capital Allocation
Beam Therapeutics Inc. invested $409.6M in research and development in fiscal year 2025. This represents an increase of 11.4% from the prior year.
Beam Therapeutics Inc. invested $14.9M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 67.1% from the prior year.
BEAM Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $31.7M-72.2% | $114.1M+1076.6% | $9.7M+14.6% | $8.5M+13.3% | $7.5M-75.2% | $30.1M+110.7% | $14.3M+21.2% | $11.8M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $104.5M+5.3% | $99.3M-9.6% | $109.8M+7.9% | $101.8M+3.0% | $98.8M-2.6% | $101.4M+7.6% | $94.3M+8.3% | $87.0M |
| SG&A Expenses | $34.4M+6.7% | $32.3M+20.7% | $26.7M-0.4% | $26.9M-3.9% | $27.9M-2.5% | $28.7M+8.1% | $26.5M-10.5% | $29.6M |
| Operating Income | -$107.2M-514.6% | -$17.4M+86.2% | -$126.8M-5.5% | -$120.2M-0.7% | -$119.3M-19.2% | -$100.0M+6.1% | -$106.5M-1.5% | -$104.9M |
| Interest Expense | $1.0M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | N/A | N/A | N/A | $0 | N/A | N/A | $39K |
| Net Income | -$94.3M-138.8% | $243.4M+315.9% | -$112.7M-10.2% | -$102.3M+5.6% | -$108.3M-19.9% | -$90.4M+6.5% | -$96.7M-6.2% | -$91.1M |
| EPS (Diluted) | $-0.91 | N/A | $-1.10-10.0% | $-1.00+18.7% | $-1.23 | N/A | $-1.17-5.4% | $-1.11 |
BEAM Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.5B0.0% | $1.5B+13.0% | $1.3B-5.8% | $1.4B-5.2% | $1.5B+32.9% | $1.1B-5.8% | $1.2B-7.1% | $1.3B |
| Current Assets | $1.3B-0.1% | $1.3B+15.5% | $1.1B-6.5% | $1.2B-5.8% | $1.2B+42.1% | $878.1M-7.1% | $945.5M-8.2% | $1.0B |
| Cash & Equivalents | $288.3M-2.3% | $294.9M+10.1% | $268.0M-5.0% | $282.1M-46.6% | $527.9M+87.2% | $282.0M+22.5% | $230.2M-21.4% | $292.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $316.4M+30.3% | $242.8M-29.6% | $345.1M+0.2% | $344.3M+0.2% | $343.8M-7.2% | $370.3M-2.6% | $380.1M-6.7% | $407.2M |
| Current Liabilities | $74.6M-23.1% | $96.9M-46.9% | $182.6M+4.8% | $174.1M+23.0% | $141.5M-22.3% | $182.1M+9.5% | $166.2M-6.3% | $177.3M |
| Long-Term Debt | $100.2M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.2B-6.0% | $1.2B+28.2% | $966.0M-7.7% | $1.0B-7.3% | $1.1B+54.0% | $733.5M-7.3% | $791.3M-7.4% | $854.1M |
| Retained Earnings | -$1.7B-5.7% | -$1.6B+13.2% | -$1.9B-6.3% | -$1.8B-6.1% | -$1.7B-7.0% | -$1.6B-6.1% | -$1.5B-7.0% | -$1.4B |
BEAM Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$128.5M-54.3% | -$83.3M-2.2% | -$81.5M-6.6% | -$76.5M+26.4% | -$103.9M-36.0% | -$76.4M+13.3% | -$88.1M-6.2% | -$83.0M |
| Capital Expenditures | $2.2M-40.2% | $3.7M-25.5% | $5.0M+59.8% | $3.1M+2.3% | $3.1M+3.2% | $3.0M+88.3% | $1.6M-19.6% | $2.0M |
| Free Cash Flow | -$130.7M-50.2% | -$87.0M-0.6% | -$86.5M-8.7% | -$79.6M+25.6% | -$106.9M-34.8% | -$79.3M+11.6% | -$89.7M-5.6% | -$85.0M |
| Investing Cash Flow | $25.3M-76.7% | $108.4M+65.1% | $65.7M+138.5% | -$170.4M-36.2% | -$125.1M-199.1% | $126.3M+411.3% | $24.7M-71.8% | $87.5M |
| Financing Cash Flow | $96.6M+5022.4% | $1.9M+12.6% | $1.7M+51.0% | $1.1M-99.8% | $473.4M+13645.0% | $3.4M+172.9% | $1.3M+848.9% | $133K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BEAM Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -337.8%-322.5pp | -15.3%+1292.3pp | -1307.6%+111.6pp | -1419.2%+177.7pp | -1596.9%-1264.2pp | -332.7%+413.7pp | -746.4%+144.7pp | -891.1% |
| Net Margin | -297.2%-510.4pp | 213.3%+1375.6pp | -1162.4%+45.9pp | -1208.3%+241.9pp | -1450.2%-1149.7pp | -300.5%+377.0pp | -677.5%+96.0pp | -773.4% |
| Return on Equity | -8.1%-27.8pp | 19.7%+31.3pp | -11.7%-1.9pp | -9.8%-0.2pp | -9.6%+2.7pp | -12.3%-0.1pp | -12.2%-1.6pp | -10.7% |
| Return on Assets | -6.4%-22.8pp | 16.4%+25.0pp | -8.6%-1.2pp | -7.3%+0.0pp | -7.4%+0.8pp | -8.2%+0.1pp | -8.3%-1.0pp | -7.2% |
| Current Ratio | 16.99+3.9 | 13.09+7.1 | 6.02-0.7 | 6.75-2.1 | 8.81+4.0 | 4.82-0.9 | 5.69-0.1 | 5.81 |
| Debt-to-Equity | 0.09-0.1 | 0.20-0.2 | 0.36+0.0 | 0.33+0.0 | 0.30-0.2 | 0.50+0.0 | 0.480.0 | 0.48 |
| FCF Margin | -412.0%-335.7pp | -76.3%+815.6pp | -891.8%+48.2pp | -940.1%+491.6pp | -1431.7%-1167.8pp | -263.9%+364.8pp | -628.6%+93.1pp | -721.8% |
Similar Companies
Frequently Asked Questions
What is Beam Therapeutics Inc.'s annual revenue?
Beam Therapeutics Inc. (BEAM) reported $139.7M in total revenue for fiscal year 2025. This represents a 120.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Beam Therapeutics Inc.'s revenue growing?
Beam Therapeutics Inc. (BEAM) revenue grew by 120% year-over-year, from $63.5M to $139.7M in fiscal year 2025.
Is Beam Therapeutics Inc. profitable?
No, Beam Therapeutics Inc. (BEAM) reported a net income of -$80.0M in fiscal year 2025, with a net profit margin of -57.2%.
What is Beam Therapeutics Inc.'s EBITDA?
Beam Therapeutics Inc. (BEAM) had EBITDA of -$361.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Beam Therapeutics Inc.'s operating margin?
Beam Therapeutics Inc. (BEAM) had an operating margin of -274.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Beam Therapeutics Inc.'s net profit margin?
Beam Therapeutics Inc. (BEAM) had a net profit margin of -57.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Beam Therapeutics Inc.'s return on equity (ROE)?
Beam Therapeutics Inc. (BEAM) has a return on equity of -6.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Beam Therapeutics Inc.'s free cash flow?
Beam Therapeutics Inc. (BEAM) generated -$360.0M in free cash flow during fiscal year 2025. This represents a -1.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Beam Therapeutics Inc.'s operating cash flow?
Beam Therapeutics Inc. (BEAM) generated -$345.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Beam Therapeutics Inc.'s total assets?
Beam Therapeutics Inc. (BEAM) had $1.5B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Beam Therapeutics Inc.'s capital expenditures?
Beam Therapeutics Inc. (BEAM) invested $14.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Beam Therapeutics Inc. spend on research and development?
Beam Therapeutics Inc. (BEAM) invested $409.6M in research and development during fiscal year 2025.
What is Beam Therapeutics Inc.'s current ratio?
Beam Therapeutics Inc. (BEAM) had a current ratio of 13.09 as of fiscal year 2025, which is generally considered healthy.
What is Beam Therapeutics Inc.'s debt-to-equity ratio?
Beam Therapeutics Inc. (BEAM) had a debt-to-equity ratio of 0.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Beam Therapeutics Inc.'s return on assets (ROA)?
Beam Therapeutics Inc. (BEAM) had a return on assets of -5.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Beam Therapeutics Inc.'s cash runway?
Based on fiscal year 2025 data, Beam Therapeutics Inc. (BEAM) had $294.9M in cash against an annual operating cash burn of $345.1M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Beam Therapeutics Inc.'s Altman Z-Score?
Beam Therapeutics Inc. (BEAM) has an Altman Z-Score of 6.52, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Beam Therapeutics Inc.'s Piotroski F-Score?
Beam Therapeutics Inc. (BEAM) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Beam Therapeutics Inc.'s earnings high quality?
Beam Therapeutics Inc. (BEAM) has an earnings quality ratio of 4.31x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Beam Therapeutics Inc.?
Beam Therapeutics Inc. (BEAM) scores 48 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.